Harmony Biosciences Holdings, Inc.

HRMY Healthcare Biotechnology

Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024. In the quarter to June 2026, revenue grew 30.3%, EPS grew 88.4%, free cash flow grew 16.5% and total debt fell 10.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.

38.20 0.07 −0.18%
Market cap
$2.2B
P/E
12.2×
Fwd P/E
9.4×
Dividend yield
—
F-score
5/9
Altman Z
5.23
Beneish M
−2.99
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Revenue

+8 more TTM periods

825.94 868.45 899.11 959.90
Gross Profit
641.74 670.11 688.25 723.99
Operating Income
225.64 208.47 189.52 230.65
EBT
230.46 215.06 197.57 241.20
Income after Tax
185.68 158.69 145.62 181.27
Net Income Common
185.68 158.69 145.62 181.27
EPS (Diluted)
3.18 2.71 2.48 3.08
Shares (Diluted, Weighted)
58.38 58.55 58.62 58.70
Gross Margin
77.70% 77.16% 76.55% 75.42%
EBIT Margin
27.32% 24.00% 21.08% 24.03%
Net Profit Margin
22.48% 18.27% 16.20% 18.88%
Free Cash Flow Margin
35.95% 40.06% 38.03% 36.99%
EBITDA
248.44 232.93 214.19 255.35
EBIT
225.64 208.47 189.52 230.65

Show all line items

In millions of $ except per-share values · columns are period end dates